Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676473 | 1.00 | HTR6 (0.65) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL28758136 | 0.99 | HTR6 (0.64) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047565 | 0.99 | HTR6 (0.64) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4315901 | 0.85 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4315898 | 0.85 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047574 | 0.84 | HTR6 (0.51) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047575 | 0.84 | HTR6 (0.51) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4312823 | 0.80 | HTR6 (0.55) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4675288 | 0.79 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL1136504 | 0.79 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | claimed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| CN-101298433-A | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy | BIOVITRUM AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-100378074-C | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | HTR6 1/4885DRD2 51/4885HTR1A 2/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | HTR6 1/4885DRD2 50/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.